UK-recruiting trials from ClinicalTrials.gov — updated daily. Filter by therapeutic area.
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female…
Sponsor: Sanofi
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress. Participants will be randomly assigned to receive either 500mg of…
Sponsor: Swansea University
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver…
Sponsor: Eli Lilly and Company
This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated…
Sponsor: Beam Therapeutics Inc.
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease…
Sponsor: Boehringer Ingelheim
This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH)…
Sponsor: Boehringer Ingelheim
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A)…
Sponsor: Regeneron Pharmaceuticals
The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it…
Sponsor: Disc Medicine, Inc
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines…
Sponsor: Eli Lilly and Company
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD). The purpose of this study is…
Sponsor: Sanofi
Get weekly clinical updates — guidelines, trials, MHRA alerts — delivered to your inbox. Free for verified HCPs.
By registering you confirm you are a healthcare professional. No spam. Unsubscribe anytime.